Clinicopathologic characteristics of HRAS mutant head and neck squamous cell carcinoma (HNSCC).

Authors:

Coral Olazagasti, Estelamari Rodriguez, Asaad Trabolsi, Samuel Kareff, Jun Yin, Phillip Walker, Trisha Michel Wise-Draper, Rebecca Chernock, Glenn J. Hanna, David Spetzler, Gilberto Lopes

Key Finding:

Mutations in HRAS are associated with poor outcomes and higher MAPK activation, PD-L1 levels, tumor mutational burden, and IFN scores in head and neck squamous cell carcinomas. 

Download Publication